AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2418305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study 29931594 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat ethyl 250 mg three times daily
Number of subjects: 0
Study 29931594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27331882 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily for 14 days
Number of subjects: 0
Study 27331882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25295771 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth technology with tailored physical activity prescription targeting changes to daily exercise, sedentary behavior, or both
Number of subjects: 45
Study 22503510 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 70
Study 20453709 — intervention group
Group type: EXPERIMENTAL
Intervention: GPO-VIR S7 chewable tablets
Number of subjects: 34
Study 20453709 — intervention group
Group type: COMPARATOR
Intervention: Liquid formulations
Number of subjects: 34
Study 18197995 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietitian-led intensive lifestyle intervention
Number of subjects: 50
Study 18197995 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 50
Study 16077744 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with 1.5 g/kg body weight of a standard amino acid
Number of subjects: 24
Study 16077744 — intervention group
Group type: COMPARATOR
Intervention: TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-glutamine
Number of subjects: 24
Study 16077744 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with glutamine supplementation (gln+)
Number of subjects: 24
Study 16077744 — intervention group
Group type: COMPARATOR
Intervention: TPN without glutamine supplementation (gln-)
Number of subjects: 24
Study 16077744 — intervention group
Group type: EXPERIMENTAL
Intervention: gln+ group
Number of subjects: 24
Study 16077744 — intervention group
Group type: COMPARATOR
Intervention: gln- group
Number of subjects: 24
Study 12208318 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0
Study 12208318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10507486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine microemulsion (CsA-NL)
Number of subjects: 380
Study 10507486 — intervention group
Group type: COMPARATOR
Intervention: Oil-based cyclosporine (CsA-SM)
Number of subjects: 380
Study 8622024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 and cyclophosphamide 1,250 mg/m2 with filgrastim 5 microG/kg/d
Number of subjects: 37
Study 8622024 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel administered first
Number of subjects: 37
Study 8622024 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide administered first
Number of subjects: 37
Study 2014934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 220 micrograms/day
Number of subjects: 305
Study 2014934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 440 micrograms/day
Number of subjects: 305
Study 2014934 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 110 micrograms/day
Number of subjects: 305
Study 2014934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 6130038 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg per day)
Number of subjects: 7
Study 6130038 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg per day)
Number of subjects: 7
Study 6130038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 6130038 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol and Propranolol
Number of subjects: 7
Study 30553916 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 receptor antagonists (three different types)
Number of subjects: 0
Study 30553916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29598883 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU/day)
Number of subjects: 180
Study 29598883 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (1000 mg/day)
Number of subjects: 180
Study 29598883 — intervention group
Group type: EXPERIMENTAL
Intervention: Both omega-3 (1000 mg/day) and vitamin D (1000 IU/day)
Number of subjects: 180
Study 29598883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 26060209 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic evaluations
Number of subjects: 45
Study 26060209 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological evaluations
Number of subjects: 45
Study 26060209 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological study
Number of subjects: 45
Study 26060209 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study group follow-up
Number of subjects: 45
Study 24837794 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose (2 initial days of double maintenance dose)
Number of subjects: 98
Study 24837794 — intervention group
Group type: COMPARATOR
Intervention: Maintenance dose (most recent maintenance dose)
Number of subjects: 98
Study 22644425 — intervention group
Group type: EXPERIMENTAL
Intervention: US fusion biopsy with MRI (n=16)
Number of subjects: 47
Study 22644425 — intervention group
Group type: EXPERIMENTAL
Intervention: US fusion biopsy with CT (n=15)
Number of subjects: 47
Study 22644425 — intervention group
Group type: COMPARATOR
Intervention: CT-guided biopsy (n=16)
Number of subjects: 47
Study 19892836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 30
Study 19892836 — intervention group
Group type: COMPARATOR
Intervention: Mixed meal in controls
Number of subjects: 30
Study 19892836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal in diabetic patients (with and without insulin)
Number of subjects: 30
Study 18541604 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 16364
Study 18541604 — intervention group
Group type: COMPARATOR
Intervention: Untreated Control
Number of subjects: 16364
Study 16195001 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent running (Loughborough Intermittent Shuttle Test) in hot conditions
Number of subjects: 9
Study 12035937 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.02 mg/kg po at ‐90 min)
Number of subjects: 7
Study 12035937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 10591421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free (L-) formula
Number of subjects: 41
Study 10591421 — intervention group
Group type: COMPARATOR
Intervention: Standard lactose-containing (L+) formula
Number of subjects: 41
Study 8696546 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization and maintenance of gastric mucosal pH (pHi) at or above 7.3
Number of subjects: 57
Study 8696546 — intervention group
Group type: COMPARATOR
Intervention: Maintenance of oxygen delivery index of 600 or an oxygen consumption index of greater than 150
Number of subjects: 57
Study 8696546 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 57
Study 2008006 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion treatment group (n = 19)
Number of subjects: 35
Study 2008006 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 35
Study 6283982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytomegalovirus immune plasma
Number of subjects: 48
Study 6283982 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 29052071 — intervention group
Group type: EXPERIMENTAL
Intervention: VBLaST training group
Number of subjects: 24
Study 29052071 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS training group
Number of subjects: 24
Study 29052071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 26955742 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP (40 mg/day) for rabbits; ATP (60 mg twice a day) for patients
Number of subjects: 44
Study 26955742 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 44
Study 25296243 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD)
Number of subjects: 200
Study 25296243 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet (CLD)
Number of subjects: 200
Study 22927836 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifid Triple Viable and Etiasa
Number of subjects: 82
Study 22927836 — intervention group
Group type: COMPARATOR
Intervention: Etiasa
Number of subjects: 82
Study 20167591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a
Number of subjects: 172
Study 20167591 — intervention group
Group type: COMPARATOR
Intervention: Control (not currently using intramuscular interferon beta-1a)
Number of subjects: 172
Study 16923824 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial infusion of 0.5% bupivacaine (group 1)
Number of subjects: 40
Study 16923824 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of fentanyl and ketorolac tromethamine (group 2)
Number of subjects: 40
Study 16234453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral recombinant tissue plasminogen activator (r-TPA) 20 microg
Number of subjects: 26
Study 16234453 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (Control)
Number of subjects: 26
Study 12142199 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (group I)
Number of subjects: 150
Study 12142199 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group II)
Number of subjects: 150
Study 9466023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%-buprenorphine at a rate of 6.3 ml.hr‐1 (2% group, n = 13)
Number of subjects: 28
Study 9466023 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 6%-buprenorphine at a rate of 2.1 ml.hr‐1 (6% group, n = 15)
Number of subjects: 28
Study 8589318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet with keto acids supplementation
Number of subjects: 12
Study 8589318 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet without keto acids supplementation
Number of subjects: 12
Study 2669939 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 100
Study 2669939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 236805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclofenac
Number of subjects: 109
Study 236805 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 109
Study 31629703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (Eze) + statins (simvastatin 10 mg, 20 mg, 40 mg, 80 mg)
Number of subjects: 0
Study 31629703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (Eze) + atorvastatin (20 mg, 40 mg)
Number of subjects: 0
Study 31629703 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy (simvastatin, atorvastatin)
Number of subjects: 0
Study 27090395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose resistance training (RT) maintenance intervention
Number of subjects: 123
Study 27090395 — intervention group
Group type: COMPARATOR
Intervention: Low-dose resistance training (RT) maintenance intervention
Number of subjects: 123
Study 24822235 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine 4 mg
Number of subjects: 45
Study 24822235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine 10 mg
Number of subjects: 45
Study 24822235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22281114 — intervention group
Group type: EXPERIMENTAL
Intervention: Py's technique (isoelastic pinning)
Number of subjects: 97
Study 22281114 — intervention group
Group type: COMPARATOR
Intervention: Kapandji's technique (intrafocal pinning)
Number of subjects: 97
Study 20078915 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with an electronic disaster simulation tool (disastermed.ca)
Number of subjects: 22
Study 20078915 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondisaster setting simulation)
Number of subjects: 22
Study 19198698 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release fluvoxamine (CR)
Number of subjects: 0
Study 19198698 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release fluvoxamine (IR)
Number of subjects: 0
Study 16807626 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 times weekly at 60% of one-repetition maximum, 9 resistance exercises, 3 sets of 15 repetitions each)
Number of subjects: 28
Study 16807626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 28
Study 14568830 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser alone
Number of subjects: 150
Study 14568830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1064-nm Nd:YAG laser alone
Number of subjects: 150
Study 14568830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of KTP and Nd:YAG lasers
Number of subjects: 150
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (1)
Number of subjects: 80
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin using the incremental technique (2)
Number of subjects: 80
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite inlay (5)
Number of subjects: 80
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic insert (6)
Number of subjects: 80
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerafil inlay (7)
Number of subjects: 80
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental glass‐fiber‐reinforced composite resins (3)
Number of subjects: 80
Study 11317400 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental direct filling using Dyract AP compomer (8)
Number of subjects: 80
Study 8823230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (oral) at doses of 3, 10, 30, 100, 300, 600, 1200, and 2400 mg
Number of subjects: 12
Study 8823230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (intravenous) at doses of 10, 50, 250, 500, and 750 mg
Number of subjects: 12
Study 8823230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (oral)
Number of subjects: 12
Study 8823230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan (intravenous)
Number of subjects: 12
Study 8823230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7949478 — intervention group
Group type: EXPERIMENTAL
Intervention: bath-PUVA therapy (30-min baths in 0.0003% 8-MOP aqueous solution, 4 times a week)
Number of subjects: 22
Study 7949478 — intervention group
Group type: COMPARATOR
Intervention: oral administration of 8-MOP
Number of subjects: 22
Study 3280317 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 40 mg three times daily
Number of subjects: 14
Study 3280317 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120 mg three times daily
Number of subjects: 14
Study 3280317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31702655 — intervention group
Group type: EXPERIMENTAL
Intervention: SIP with concurrent auditory cues (AC condition)
Number of subjects: 0
Study 31702655 — intervention group
Group type: COMPARATOR
Intervention: SIP without auditory cues (NC condition)
Number of subjects: 0
Study 28598705 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT combined with TAU (n=59)
Number of subjects: 181
Study 28598705 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT combined with TAU (n=86)
Number of subjects: 181
Study 28598705 — intervention group
Group type: COMPARATOR
Intervention: TAU only (n=36)
Number of subjects: 181
Study 27341793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention sites with quarterly workplace assessments and offering HIV treatment at OHUs
Number of subjects: 1372
Study 27341793 — intervention group
Group type: COMPARATOR
Intervention: Comparison sites with bi-annual infection control assessments
Number of subjects: 1372
Study 27341793 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall healthcare worker services
Number of subjects: 1372
Study 23468262 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg/kg bolus of remifentanil
Number of subjects: 54
Study 23468262 — intervention group
Group type: COMPARATOR
Intervention: 0.5 µg/kg bolus of remifentanil
Number of subjects: 54
Study 21575095 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of differentiated adipocytes
Number of subjects: 31
Study 19033260 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 826
Study 17079789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided placement
Number of subjects: 60
Study 17079789 — intervention group
Group type: COMPARATOR
Intervention: Palpation placement
Number of subjects: 60
Study 15645904 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-phase, calcium-containing, bicarbonate-based toothpaste
Number of subjects: 0
Study 15645904 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental, two-phase, calcium-containing, bicarbonate-free toothpaste
Number of subjects: 0
Study 15645904 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothpaste
Number of subjects: 0
Study 15645904 — intervention group
Group type: EXPERIMENTAL
Intervention: All three toothpastes
Number of subjects: 0
Study 15645904 — intervention group
Group type: EXPERIMENTAL
Intervention: Two calcium-containing toothpastes
Number of subjects: 0
Study 11245647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 703
Study 11245647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703
Study 8846523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (5.04 ± 0.60 g daily, 10.1 ± 1.20 tablets of 500 mg)
Number of subjects: 53
Study 8846523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (2.71 ± 0.48 g daily, 5.4 ± 0.95 capsules of 500 mg) with aluminum hydroxide (0.69 ± 0.27 g daily, 1.4 ± 0.55 tablets of 500 mg)
Number of subjects: 53
Study 8846523 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide
Number of subjects: 53
Study 1659052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oka/Merck varicella vaccine
Number of subjects: 22
Study 1659052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6742382 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine with adrenaline 1:200 000
Number of subjects: 19
Study 6742382 — intervention group
Group type: COMPARATOR
Intervention: prilocaine 0.5% with octapressin 0.03 iu per ml
Number of subjects: 19
Study 31785093 — intervention group
Group type: EXPERIMENTAL
Intervention: Second harmonic generation (SHG) microscopy and optical scattering measurements
Number of subjects: 0
Study 31785093 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelength‐dependent optical scattering measurements
Number of subjects: 0
Study 31785093 — intervention group
Group type: EXPERIMENTAL
Intervention: SHG circular dichroism
Number of subjects: 0
Study 29615058 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) treatment
Number of subjects: 43
Study 26266260 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Zataria multiflora cream
Number of subjects: 420
Study 26266260 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole pill
Number of subjects: 420
Study 23396375 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed generic formulation of S-1 (40 mg/m(2), po)
Number of subjects: 30
Study 23396375 — intervention group
Group type: COMPARATOR
Intervention: Branded reference formulation of S-1 (40 mg/m(2), po)
Number of subjects: 30
Study 23396375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of S-1
Number of subjects: 30
Study 21922361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 25
Study 21922361 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 25
Study 19519724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (8 mg/kg)
Number of subjects: 60
Study 19519724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17449541 — intervention group
Group type: EXPERIMENTAL
Intervention: Test protocol (7 days' training with exercise and neck suction)
Number of subjects: 8
Study 17449541 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (exercise alone)
Number of subjects: 8
Study 17449541 — intervention group
Group type: COMPARATOR
Intervention: Control protocol (neck suction alone)
Number of subjects: 8
Study 15096532 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure intervention (writing about traumas and stressors for 20 minutes on three different days)
Number of subjects: 54
Study 15096532 — intervention group
Group type: COMPARATOR
Intervention: Control group (writing about summer activities for 20 minutes on three different days)
Number of subjects: 54
Study 11673220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling pairs
Number of subjects: 392
Study 11673220 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-concordant sibling pairs
Number of subjects: 392
Study 11673220 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking-discordant siblings
Number of subjects: 392
Study 9551002 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including behavioral curricula, parental involvement, school food service changes, and industry support.
Number of subjects: 20
Study 8794428 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement treatment (HRT) with transdermal 17 beta‐estradiol, 50 mg/day for 24 days/month and medroxiprogesterone, 10 mg for 12 days
Number of subjects: 104
Study 8794428 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium treatment with elemental calcium, 1 g/day
Number of subjects: 104
Study 8794428 — intervention group
Group type: EXPERIMENTAL
Intervention: Eel calcitonin treatment with 40 IU/day for 10 days/month and elemental calcium, 500 mg/day
Number of subjects: 104
Study 8794428 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 104